Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL: Maternal or Neonatal PCV13 Vaccination for Infant Pneumococcal Carriage
NCT02628886Phase 3Unknown
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Mar 2016
- Primary completion
- Feb 2019
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 13-valent conjugate vaccine in pneumonia and pneumococcal infection, sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Safety in pregnant mothers (Serious Adverse Events). Status: unknown.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumoniapneumococcal infection
Beyond the preview
Go deeper on NCT02628886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02628886.